The products in the United States include ABILIFY® (aripiprazole) Tablets
1 and PLETAL® (cilostazol) Tablets2
ABILIFY is a medication
for the treatment of schizophrenia and acute manic and mixed
episodes associated with Bipolar I Disorder. The
Otsuka-discovered compound is co-promoted with Bristol-Myers
Squibb Co. The compound received approval from the FDA in
November 2002.
For more information on ABILIFY® (aripiprazole) Tablets , please visit www.abilify.com.
PLETAL is a medication used to treat the
symptoms of intermittent claudication, which is associated
with peripheral arterial disease. The compound received
approval from the FDA in January 1999.
|
|
1 Please see FULL PRODUCT INFORMATION including for ABILIFY.
2 Please see FULL PRODUCT INFORMATION including for PLETAL.
|
